SOURCE: HTG Molecular Diagnostics

HTG Molecular Diagnostics

March 30, 2012 07:00 ET

HTG Molecular Diagnostics and Sanofi US Collaborate to Identify B-cell Malignancy Biomarkers

Development of Tests That Help Identify Patients Most Likely to Respond to Targeted Therapy Is a Key Step Toward the Personalization of Medicine

TUCSON, AZ--(Marketwire - Mar 30, 2012) - HTG Molecular Diagnostics has established a collaborative program with Sanofi US to identify biomarkers that may lead to the development of a molecular companion diagnostic test to help identify patients most likely to respond to a novel Sanofi investigational agent. HTG Molecular Diagnostics' qNPA technology measures mRNA and/or miRNA expression in formalin fixed paraffin embedded (FFPE) tumor samples, allowing clinicians to verify the presence of certain biomarkers relevant to patient selection and therapy.

"We are pleased to be a partner with Sanofi in answering the need for personalized cancer treatments. qNPA offers options in diagnostics testing of FFPE tissues not available in other commercial technologies," said TJ Johnson, CEO of HTG Molecular Diagnostics.

HTG Molecular Diagnostics is a privately-held, Tucson-based company providing products for gene expression profiling, miRNA, siRNA and mRNA measurement for clinical research, companion diagnostic and prognostic applications in oncology. The company's qNPA molecular technology platform is well-suited for reliably detecting changes in gene expression levels especially from formalin-fixed, paraffin-embedded (FFPE) tissue. Additional information is available at

Contact Information

  • Media Contact:
    Kimberly Schmitz
    Spur Public Relations.
    Email Contact

    Company Contact:
    TJ Johnson
    Chief Executive Officer
    HTG Molecular Diagnostics
    Email Contact